Bal Pharma Limited has announced its unaudited financial results for the quarter and half-year ended September 30, 2025, along with the appointment of a new independent director to its board.

Financial Performance

For the quarter ended September 30, 2025, Bal Pharma reported a standalone revenue from operations of Rs 7,374.95 lakhs, compared to Rs 7,470.02 lakhs in the same quarter of the previous year. The company's net profit for the quarter stood at Rs 78.17 lakhs, showing an improvement from Rs 32.31 lakhs in the previous quarter but a decrease from Rs 114.33 lakhs in the corresponding quarter of the previous year.

Key Financial Highlights (Standalone):

For the half-year ended September 30, 2025, the company's revenue from operations was Rs 13,938.46 lakhs, with a net profit of Rs 110.48 lakhs.

Appointment of New Independent Director

Bal Pharma has appointed Dr. Bheekamchand Mukesh as an Additional Non-executive Independent Director. Dr. Mukesh, who holds a DIN of 11295580, brings approximately 35 years of experience in pharmaceutical research, development, and commercialization.

Key details of Dr. Mukesh's appointment:

• Date of Birth: 07/05/1968
• Date of Appointment: 12/11/2025
• Educational Qualification: Doctor
• Expertise: Research & Development and commercialization of pharma products

Dr. Mukesh's appointment is subject to approval at the next Annual General Meeting, Postal Ballot, or Extraordinary General Meeting of the company. The company has confirmed that Dr. Mukesh is not debarred from holding the office of Director by virtue of any SEBI order or any other statutory authority.

Auditor's Review

The statutory auditors of the company, SSJNB & Co, Chartered Accountants, have issued their limited review report with an unmodified opinion on the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025.

Bal Pharma's management expressed confidence in the company's performance and future prospects, highlighting the strategic importance of Dr. Mukesh's appointment in strengthening the company's research and development capabilities.

The company continues to focus on its core pharmaceutical segment, with ongoing efforts to enhance operational efficiency and market presence.

Bal Pharma Limited, a pharmaceutical company, has postponed its decision on the proposed merger of its subsidiary, Lifezen Healthcare Pvt Ltd, with the parent company. The deferment comes as a result of insufficient information available to the Board of Directors during their recent meeting.

Board Meeting Outcome

The company's Board of Directors convened to discuss several agenda items, including the potential merger. However, when it came to the merger proposal, the board found the available data inadequate for making an informed decision. As a result, they have instructed the management to re-present the proposal with all necessary details.

Timeline of Events

To provide a clear picture of the sequence of events, here's a breakdown:

Implications and Next Steps

The deferment of the merger decision highlights the company's commitment to thorough evaluation before making significant corporate decisions. By requesting more comprehensive data, the Board of Directors demonstrates a cautious approach to potential structural changes within the organization.

Investors and stakeholders will likely be watching closely for any updates on this matter. The company is expected to present a more detailed proposal in a future board meeting, although no specific timeline has been provided for when this re-presentation might occur.

It's worth noting that while the merger was initially included as an agenda item, the board's decision to postpone rather than reject outright suggests that the proposal may still be under consideration, pending more complete information.

As this situation develops, shareholders and market observers will be keen to understand the potential impacts of the proposed merger on Bal Pharma's operations, financial structure, and overall strategy. The market's reaction to this deferment and any subsequent announcements will be important indicators of investor sentiment towards the company's corporate actions.

Bal Pharma Limited continues to operate as usual, with its subsidiary Lifezen Healthcare Pvt Ltd remaining a separate entity for the time being. Further updates on this matter are anticipated as the company prepares a more comprehensive merger proposal for future consideration.